Table 3.
COH characteristics of patients in MetS group and control group
| MetS group | Control group | P value | |
|---|---|---|---|
| (n = 1147) | (n = 7392) | ||
| Days of ovarian stimulation (d) | 10.35 (9.02-11.95) | 9.62 (8.41-10.94) | <.001 |
| Starting dose of Gn (IU) | 171.75 (145.18-215.04) | 153.95 (140.33-188.46) | <.001 |
| Total dose of Gn (IU) | 2163.64 (1602.68-2926.97) | 1621.13 (1274.27-2239.75) | <.001 |
| COH protocol (%) | .193 | ||
| GnRH agonist long | 528/1147 (46.0) | 3671/7392 (49.7) | |
| GnRH agonist short | 206/1147 (18.0) | 1234/7392 (16.7) | |
| GnRH agonist ultralong | 97/1147 (8.5) | 584/7392 (7.9) | |
| GnRH antagonist | 281/1147 (24.5) | 1723/7392 (23.3) | |
| Others | 35/1147 (3.1) | 180/7392 (2.4) | |
| LH on trigger day (IU/L) | 2.26 (1.37-3.53) | 2.24 (1.55-3.87) | <.001 |
| E2 on trigger day (pg/mL) | 2520.00 (1640.00-3639.75) | 3001.78 (2099.33-4593.00) | <.001 |
| Progesterone on trigger day (ng/mL) | 0.55 (0.36-0.81) | 0.64 (0.45-0.90) | <.001 |
Results are expressed as median (25-75%) or n (%).
Abbreviations: COH, controlled ovarian hyperstimulation; E2, estradiol; Gn, gonadotropin; LH, luteinizing hormone; MetS, metabolic syndrome.